RSS-Feed abonnieren
DOI: 10.1055/s-0031-1280664
Transarterial Chemoembolization Complicated by Deteriorating Hepatic Function
Publikationsverlauf
Publikationsdatum:
16. Juni 2011 (online)
![](https://www.thieme-connect.de/media/sir/201102/lookinside/thumbnails/10.1055-s-0031-1280664-1.jpg)
ABSTRACT
Worsening hepatic function is a well-known potential complication of chemoembolization and occurs in up to 58% of patients undergoing chemoembolization. Although liver function returns to baseline levels within 3–4 weeks in the majority of patients, fulminant liver failure and death occur with a reported frequency of ~2–10%. Poor performance status, portal vein obstruction, biliary obstruction, extensive tumor burden, and Child-Pugh status B or C are among factors predisposing to an increased risk of transient or fulminant hepatic failure, with Child-Pugh status being the most accurate. Unless the patient is a candidate for liver transplantation, treatment for hepatic failure is limited to supportive measures.
KEYWORDS
Chemoembolization - liver failure - complications
REFERENCES
- 1 Hong K, McBride J D, Georgiades C S et al.. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009; 20 (3) 360-367
- 2 Kingham T P, D'Angelica M, Kemeny N E. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol. 2010; 102 (8) 988-995
- 3 Gee M, Soulen M C. Chemoembolization for hepatic metastases. Tech Vasc Interv Radiol. 2002; 5 (3) 132-140
- 4 Gonsalves C F, Brown D B. Chemoembolization of hepatic malignancy. Abdom Imaging. 2009; 34 (5) 557-565
- 5 Liapi E, Georgiades C C, Hong K, Geschwind J F. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007; 10 (1) 2-11
- 6 Marelli L, Stigliano R, Triantos C et al.. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007; 30 (1) 6-25
- 7 Huang Y S, Chiang J H, Wu J C, Chang F Y, Lee S D. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol. 2002; 97 (5) 1223-1227
- 8 Kothary N, Weintraub J L, Susman J, Rundback J H. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 2007; 18 (12) 1517-1526, quiz 1527
- 9 Georgiades C S, Liapi E, Frangakis C et al.. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2006; 17 (10) 1619-1624
- 10 Chung J W, Park J H, Han J K et al.. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology. 1996; 198 (1) 33-40
- 11 Kiely J M, Rilling W S, Touzios J G et al.. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol. 2006; 17 (1) 47-53
- 12 Paye F, Farges O, Dahmane M, Vilgrain V, Flejou J F, Belghiti J. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg. 1999; 86 (2) 176-180
Reed A OmaryM.D. M.S.
Professor of Radiology and Biomedical Engineering, Vice Chair of Research, Department of Radiology, Section of Interventional Radiology, Northwestern University Feinberg School of Medicine
737 N. Michigan Avenue, Suite 1600, Chicago, IL 60611
eMail: reed@northwestern.edu